NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
1 Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121 1066 CX, Amsterdam, The Netherlands
2 Department of Radiation Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The Netherlands
3 Department of Pulmonology and GROW – School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands
4 Department of Radiation Oncology, Maastro, Maastricht, The Netherlands and University Hospitals Leuven/KU Leuven, Leuven, Belgium
5 Merck KGaA, Darmstadt, Germany
6 EMD Serono, Billerica, MA, USA subsidiary of Merck KGaA, Darmstadt, Germany
7 Present address: Novartis Pharma, Basel, Switzerland